Skip to main content
. 2012 Nov 14;32(46):16106–16119. doi: 10.1523/JNEUROSCI.6408-11.2012

Figure 4.

Figure 4.

In vivo specificity of NOP receptor agonists. A, B, Ro 65–6570 (0.01–1 mg/kg, i.p.) inhibited stepping activity in the drag test in NOP+/+ mice, being ineffective in NOP−/− mice. Each experiment consisted of three different sessions: a control session followed by two other sessions performed 15 min (A) and 90 min (B) after saline or drug administration. Data are expressed as percentages of motor performance in the control session and are means ± SEM 6–7 determinations per group. C, D, NOP receptor antagonists prevent the antidyskinetic effect of NOP receptor agonists. UFP-101 (10 nmol, i.c.v.) was administered simultaneously with N/OFQ (0.1 nmol, i.c.v.; C) or 5 min before Ro 65–6570 (0.1 mg/kg, i.p.; D). J-113397 (3 mg/kg, i.p.) was administered 15 min before NOP agonists. Data are expressed as percentages of l-DOPA effect, and are means ± SEM of 10–12 determinations per group. Statistical analysis was performed by one-way ANOVA followed by the Newman–Keuls test for multiple comparisons. A, Significant effect of treatment in NOP+/+ mice (F(3,23) = 17.61, p < 0.0001). B, Significant effect of treatment in NOP+/+ mice (F(3,23) = 19.89, p < 0.0001). *p < 0.05, **p < 0.01, different from saline. °°p < 0.01, different from N/OFQ or Ro 65–6570 alone.